This report was first published by Endpoints News. To see the original version, click here
Ken Song has done it again.
The biopharma veteran’s all-out effort to prove T cell engagers’ potential in autoimmune diseases is getting picked up by one of Europe’s oldest pharma companies.
您已阅读6%（279字），剩余94%（4133字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。